{
    "clinical_study": {
        "@rank": "95724", 
        "arm_group": [
            {
                "arm_group_label": "Eravacycline, 1.0 mg/kg q12h", 
                "arm_group_type": "Experimental", 
                "description": "Eravacycline, 1.0 mg/kg q12h administered via IV infusion, plus saline placebo"
            }, 
            {
                "arm_group_label": "Ertapenem, 1 g q24h", 
                "arm_group_type": "Active Comparator", 
                "description": "Ertapenem, 1 g q24h administered via IV infusion, plus saline placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to\n      assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in\n      the treatment of adult complicated intra-abdominal infections (cIAI)."
        }, 
        "brief_title": "Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Complicated Intra-abdominal Infections", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female subject hospitalized for complicated intra-abdominal infection\n\n          2. At least 18 years of age (and not over 65 years of age for subjects in India)\n\n          3. Evidence of a systemic inflammatory response\n\n          4. Abdominal pain or flank pain (with or without rebound tenderness), or pain caused by\n             cIAI that is referred to another anatomic area\n\n          5. Able to provide informed consent\n\n          6. If male: must agree to use an effective barrier method of contraception during the\n             study and for 90 days following the last dose if sexually active with a female of\n             childbearing potential\n\n          7. If female, not pregnant or nursing or, if of childbearing potential: either will\n             commit to use at least two medically accepted, effective methods of birth control\n             (e.g., condom, oral contraceptive, indwelling intrauterine device, hormonal implant\n             /patch, injections, approved cervical ring) during study drug dosing and for 90 days\n             following last study drug dose or practicing sexual abstinence\n\n        Exclusion Criteria:\n\n          1. Unlikely to survive the 6-8 week study period\n\n          2. Renal failure\n\n          3. Presence or possible signs of hepatic disease\n\n          4. Immunocompromised condition, including known HIV positivity (requiring\n             anti-retroviral therapy or with CD4 count <300), AIDS, organ (bone marrow) transplant\n             recipients, and hematological malignancy. Immunosuppressive therapy, including use of\n             high-dose corticosteroids (e.g., > 40 mg prednisone or equivalent per day for greater\n             than 2 weeks)\n\n          5. History of hypersensitivity reactions to tetracyclines, carbapenems, \u03b2-lactam\n             antibiotics or to excipients contained in the study drug formulations\n\n          6. Participation in any investigational drug or device study within 30 days prior to\n             study entry\n\n          7. Known or suspected current Central Nervous System disorder that may predispose to\n             seizures or lower seizure threshold\n\n          8. Previously received eravacycline in a clinical trial\n\n          9. Antibiotic-related exclusions:\n\n               1. Receipt of effective antibacterial drug therapy for cIAI for a continuous\n                  duration of > 24-h during the 72-h preceding enrollment (however, subjects with\n                  documented cIAI (i.e., known baseline pathogen) who have received at least 72-h\n                  of antibiotic therapy and are considered treatment failures may be enrolled.\n                  Treatment failure is defined as persistent fever and/or clinical symptoms; or\n                  the development of a new intra-abdominal abscess after \u2265 72-h of antibiotic\n                  therapy), or\n\n               2. Receipt of ertapenem or any other carbapenem, or tigecycline for the current\n                  infection or\n\n               3. Need for concomitant systemic antimicrobial agents other than study drug\n\n         10. Refusal of mechanical ventilation, dialysis or hemofiltration, cardioversion or any\n             other resuscitative measures and drug/fluid therapy at time of consent\n\n         11. Known or suspected inflammatory bowel disease or associated visceral abscess\n\n         12. The anticipated need for systemic antibiotics for a duration of more than 14 days\n\n         13. Systemic malignancy that required chemotherapy, immunotherapy, radiation therapy or\n             antineoplastic therapy within the previous 3 months or that is anticipated to begin\n             prior to the TOC visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "536", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844856", 
            "org_study_id": "TP-434-008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Eravacycline, 1.0 mg/kg q12h", 
                "description": "Eravacycline reconstituted and administered via an IV infusion", 
                "intervention_name": "Eravacycline", 
                "intervention_type": "Drug", 
                "other_name": "TP-434"
            }, 
            {
                "arm_group_label": "Ertapenem, 1 g q24h", 
                "description": "Ertapenem reconstituted and administered via an IV infusion", 
                "intervention_name": "Ertapenem", 
                "intervention_type": "Drug", 
                "other_name": "Invanz\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ertapenem"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallinn", 
                        "country": "Estonia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vilnius", 
                        "country": "Lithuania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pretoria", 
                        "country": "South Africa"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiev", 
                        "country": "Ukraine"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Bulgaria", 
                "Czech Republic", 
                "Estonia", 
                "France", 
                "Germany", 
                "India", 
                "Latvia", 
                "Lithuania", 
                "Romania", 
                "Russian Federation", 
                "South Africa", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections", 
        "overall_contact": {
            "email": "amarsh@tphase.com", 
            "last_name": "Andrew Marsh", 
            "phone": "617-600-4996"
        }, 
        "overall_contact_backup": {
            "email": "klloyd@tphase.com", 
            "last_name": "Kevin Lloyd", 
            "phone": "617-715-3589"
        }, 
        "overall_official": {
            "affiliation": "Tetraphase Pharmaceuticals, Inc.", 
            "last_name": "Patrick T. Horn, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Clinical response of eravacycline and ertapenem treatment arms at the test-of-cure (TOC) visit in the microbiological intent-to-treat (micro-ITT) population", 
            "safety_issue": "No", 
            "time_frame": "TOC: 25-31 days after the first dose of study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844856"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Compare clinical response in the following populations: 1) Intent -to-treat (ITT) population, 2) Clinically evaluable (CE) population, 3) Micro-ITT population (for EOT, FU), 4) Microbiologically evaluable (ME) population.", 
                "measure": "Clinical response of eravacycline and ertapenem treatment arms at the end-of-treatment (EOT), TOC, and follow-up(FU) visits", 
                "safety_issue": "No", 
                "time_frame": "EOT: within 24 hours of last dose; TOC: 25-31 days after first dose; FU: 38-50 days after first dose"
            }, 
            {
                "description": "Compare the microbiological response in the following populations: 1) Micro-ITT population, 2) ME population.", 
                "measure": "Microbiologic response of eravacycline and ertapenem treatment arms at the EOT and TOC visits", 
                "safety_issue": "No", 
                "time_frame": "EOT: within 24 hours of last dose; TOC: 25-31 days after first dose"
            }, 
            {
                "description": "Describe the safety profile of eravacycline", 
                "measure": "Assess safety and tolerability of eravacycline (Adverse Events, Physical Exams, Vital signs, ECGs, Lab Data) in the safety population", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Days 1-14, EOT, TOC, FU"
            }, 
            {
                "description": "Evaluate the pharmacokinetics of eravacycline", 
                "measure": "Explore pharmacokinetic parameters after eravacycline infusion", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "source": "Tetraphase Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tetraphase Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}